PharmAbcine Appoints World-Renowned Molecular Biologist Dr. Napoleone Ferrara to Scientific Advisory Board

DAEJEON, Republic of Korea, March 00, 2019 / PharmAbcine Inc. (KOSDAQ: 208340), a biopharmaceutical company focused on the development of next generation bio-therapeutics in medical unmet needs, announced today the appointment of Napoleone Ferrara, M.D., to its Scientific Advisory Board. Dr. Ferrara is a world-leading molecular biologist in the field of pathological angiogenesis. He is recognized for a number of scientific achievements. Most notably, Dr. Ferrara is credited with the discovery of vascular endothelial growth factor (VEGF) and the first anti-VEGF antibody which suppresses the growth of a variety of tumors. These breakthrough discoveries played an integral role in the development of the first commercially available angiogenesis inhibitor, Avastin® (bevacizumab), which prevents the growth of new blood vessels in a solid tumor and has become part of the standard treatment regimen for a variety of cancers.

"On behalf of the management team and Board, I am extremely pleased to welcome Dr. Ferrara to PharmAbcine. Dr. Ferrara's outstanding scientific expertise and experience in both oncology and ophthalmology will be a tremendous asset as we continue to advance the development of TTAC-0001, PMC-001, PMC-002R, PMC-201, PMC-402 and PMC-401s. Additionally, we look forward to Dr. Ferrara's guidance in evaluating future product portfolio expansion opportunities, including TTAC-0001's use in Keytruda combination therapies for refractory cancers," said Dr. Jin-San Yoo, CEO and Chairman of PharmAbcine's Board of Directors.

Dr. Ferrara is currently a distinguished professor of pathology and a distinguished adjunct professor of ophthalmology and pharmacology at the University of California, San Diego. He is a pioneer in the study of angiogenesis biology and identification of its regulators. He is a pioneer in the study of angiogenesis biology and identification of its regulators. Ferrara's work also led to the clinical development of an anti-VEGF antibody fragment, Lucentis® (ranibizumab), as a highly effective therapy preventing vision loss in intraocular neovascular disorders. Dr. Ferrara has been the recipient of over 60 awards/honors, given more than 300 presentations, authored over 70 patents, and written more than 300 articles, reviews/editorials and published book chapters. He received his fellowship training and postdoctoral research from the University of California, San Francisco, his M.D. (cum laude) and residency training from the University of Catania Medical School, and his Maturita' Classica from Liceo Classico Mario Cutelli.

"I am delighted to join PharmAbcine's Scientific Advisory Board at such a critical time in the Company's development," said Dr. Ferrara. "Based on the data generated to

date and its profile, I believe TTAC-0001 has the potential to be effective against a wide range of solid tumor cancers. I look forward to working closely with PharmAbcine's management team and the Board to continue fostering the Company's future TTAC-0001 development, including the potential of combination therapies for oncology patients for no viable alternatives."

About PharmAbcine, Inc.

PharmAbcine Inc. is a leading clinical stage biopharmaceutical company that develops fully human therapeutic antibody (mAb) and next generation multispecific antibody therapeutics based on in-house developed novel platform, DIG-Body, PIG-Body and TIG-Body using innovative discovery technology and excellent human resources for the treatment of human diseases, such as cancer and inflammatory diseases.

PharmAbcine's fully human antibody libraries and innovative selection system are our priceless proprietary assets. PharmAbcine provides antibody generation services by using antibody library and selection systems. PharmAbcine also provides co-development opportunities with novel antibodies.

Under the collaboration with SAMSUNG MEDICAL CENTER, PharmAbcine has more than 300 patients derived cancer stem cell libraries and its animal model system for evaluating internal pipeline development.

Selected pipeline.

TTAC-0001(Tanibirumab): anti-KDR neutralizing fully human IgG with unique cross species cross reactivity has completed its Phase IIa recurrent GBM trial in Australia in August 2017. Promising molecule to combine with immune checkpoint blockade is open for out-licensing, co-development and combination clinical trials.

PMC-001(DIG-KT): next generation bispecific antibody neutralizing both VEGF-KDR and Angiopoietin-TIE2 pathways is superior to bevacizumab and Tanibirumab in preliminary studies. It also overcomes the Avastin® resistant brain tumor growth. Both PMC-002 and PMC-002R are different scaffolds neutralizing same targets like PMC-001.

PMC-201: next generation bispecific antibody neutralizing both VEGF-KDR and Notch-DLL4 pathways overcomes anti-cancer drug resistant tumor growth.

PMC-005BL: Anti-EGFRviii truly specific fully human IgG with internalization property is perfect for ADC, CAR-T and CAR-NK purpose and is open for co-development or out-licensing.

PMC-309a-z: anti-VISTA fully human antibodies collection as either agonistic or antagonistic. Antagonistic antibody performed synergy effects in combination with other immuno-oncology drug.

"3G-System" platform provides high performing production cell lines and we do have both

PMC-901: bevacizumab biosimilar cell line with 3g/L productivity.
PMC-902: aflibercept biosimilar cell line with > 3g/L productivity.

For additional information about PharmAbcine is available through its website, http://www.pharmabcine.com